Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study (DREAM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03067285
Recruitment Status : Completed
First Posted : March 1, 2017
Last Update Posted : August 27, 2019
Sponsor:
Information provided by (Responsible Party):
Fundacion SEIMC-GESIDA

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : April 23, 2019
Actual Study Completion Date : April 23, 2019